Now listed on Nasdaq Stockholm
Aktiedagen Stockholm – May 2, 2022
Sedermeradagen – April 25, 2022
AP1189
A Novel and First-in-Class Agent to Target the Melanocortin System
Our drug candidate AP1189, a once-daily oral selective melanocortin agonist, specifically stimulates melanocortin receptors to help the body resolve inflammation. SynAct is currently evaluating AP1189 in rheumatoid arthritis (RA), in idiopathic membranous nephropathy (iMN, an autoimmune disease associated with the development of nephrotic syndrome) and in the treatment of respiratory insufficiency caused by viruses like COVID-19.
-
September 30, 2022 Non RegulatorySynAct Pharma submits IND for US Phase 2a/b clinical trial
-
September 27, 2022 Non RegulatorySynAct Pharma enrolls first patient in Phase 2b trial of AP1189 in RA
-
August 5, 2022 RegulatorySynAct Pharma publishes Q2 2022 interim report
-
May 30, 2022 RegulatorySynAct Pharma publishes Q1 2022 interim report
A MESSAGE FROM OUR CEO